Modulation of 5-fluorouracil-induced toxicity in mice with interferon or with the interferon inducer, polyinosinic-polycytidylic acid - PubMed (original) (raw)
- PMID: 6184150
Modulation of 5-fluorouracil-induced toxicity in mice with interferon or with the interferon inducer, polyinosinic-polycytidylic acid
R L Stolfi et al. Cancer Res. 1983 Feb.
Abstract
Partially purified preparations of mouse interferon, administered during the 2-day period following the administration of a toxic dose of 5-fluorouracil (FUra), yielded significant protection from mortality in BALB/c X DBA/2 F1 mice. Protection against FUra-induced toxicity was also observed when the interferon inducer polyinosinic-polycytidylic acid (poly I X poly C) was administered with FUra. The temporal relationship between the administration of poly I X poly C and FUra was found to be a critical determinant of the intensity of toxic manifestations. In relation to FUra alone, poly I X poly C could enhance (when administered 48 hr before FUra), diminish (when administered together with FUra), or not affect (when administered 48 hr after FUra) the degree of resultant toxicity. Cytofluorometric analysis of the DNA content of bone marrow cells indicated a transient period (about 42 hr) of inhibition of cell cycling following the administration of poly I X poly C, followed by reentry into cycle (between 42 and 66 hr) and a return to normal cycle phase distribution by 90 hr. This disturbance of the kinetic pattern of cell cycling in bone marrow would explain the administration time-dependent variability of the effect of poly I X poly C on FUra toxicity, since FUra is known to be a cell cycle-specific cytotoxic drug. Potential practical application of this observation to the clinical use of FUra in cancer therapy is discussed.
Similar articles
- Modulation of chemotherapeutic drug activity with polyribonucleotides or with interferon.
Stolfi RL, Martin DS. Stolfi RL, et al. J Biol Response Mod. 1985 Dec;4(6):634-9. J Biol Response Mod. 1985. PMID: 2418161 - 5-Fluorouracil incorporation into DNA of CF-1 mouse bone marrow cells as a possible mechanism of toxicity.
Schuetz JD, Wallace HJ, Diasio RB. Schuetz JD, et al. Cancer Res. 1984 Apr;44(4):1358-63. Cancer Res. 1984. PMID: 6704957 - Use of uridine rescue to enhance the antitumor selectivity of 5-fluorouracil.
Klubes P, Cerna I. Klubes P, et al. Cancer Res. 1983 Jul;43(7):3182-6. Cancer Res. 1983. PMID: 6850628 - Experimental ocular studies with polyinosinic acid: polycytidylic acid.
McDonald TO. McDonald TO. Eye Ear Nose Throat Mon. 1973 Feb;52(2):45-52. Eye Ear Nose Throat Mon. 1973. PMID: 4346077 Review. No abstract available.
Cited by
- A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma.
Rohatiner A, Radford J, Deakin D, Earl H, Love SB, Price O, Wilson A, Lister TA. Rohatiner A, et al. Br J Cancer. 2001 Jul 6;85(1):29-35. doi: 10.1054/bjoc.2001.1822. Br J Cancer. 2001. PMID: 11437398 Free PMC article. Clinical Trial. - Pharmacokinetic interaction of 5-fluorouracil and interferon alpha-2b with or without folinic acid.
b1p6uller J, Czejka M. b1p6uller J, et al. Med Oncol. 1995 Mar;12(1):47-53. doi: 10.1007/BF01571408. Med Oncol. 1995. PMID: 8542247 Clinical Trial. - Double modulation of 5-fluorouracil by high-dose leucovorin and interferon alpha 2b in advanced colorectal cancer: a phase I and a phase II study of weekly administration.
Steger GG, Mader RM, Djavanmard MP, Gnant MF, Locker G, Marosi C, Rainer H, Jakesz R. Steger GG, et al. J Cancer Res Clin Oncol. 1994;120(5):314-8. doi: 10.1007/BF01236390. J Cancer Res Clin Oncol. 1994. PMID: 8126062 Clinical Trial. - Effective treatment of liver metastases from colon cancer with a combination of gamma-interferon and cisplatin chemotherapy: report of a case.
Kohara N, Kitaoka F, Komuta K, Yamamoto M, Motojima K, Kanematsu T. Kohara N, et al. Surg Today. 1995;25(4):357-60. doi: 10.1007/BF00311260. Surg Today. 1995. PMID: 7633128 - New targets for pyrimidine antimetabolites in the treatment of solid tumours. 1: Thymidylate synthase.
van der Wilt CL, Peters GJ. van der Wilt CL, et al. Pharm World Sci. 1994 Apr 15;16(2):84-103. doi: 10.1007/BF01880660. Pharm World Sci. 1994. PMID: 7518280 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources